Comparative Study Of The Clinical Efficacy Between Ticagrelor And Clopidogrel In Patients With Acute Coronary Syndrome And Type 2 Diabetes Mellitus After Percutaneous Coronary Intervention

ObjectiveComparative Study of the Clinical Efficacy between Ticagrelor and Clopidogrel in Patients with Acute Coronary Syndrome and Type 2 Diabetes Mellitus after Percutaneous Coronary Intervention.MethodsIn our hospital,115 patients with diabetes syndrome who underwent acute coronary surgery in the treatment of coronary intervention,were randomly divided into Grenada for ticagrelor(Group A,n=52)and Clopidogrel(Group B,n=63)group.Group A were treated 300 mg ticagrel and 180 mg aspirin preoperatively,and 90 mg ticagrelor postoperatively,2 time /day;Group B received the loading dose of clopidogrel aspirin for 300 mg before surgery,75 mg for clopidogrel and aspirin for 100 mg after surgery,1 time/day to maintain.All patients received intravenous blood collection before and after PCI two months later and four months later.The platelet function indexes CD62 P,CD63 and MPAR were measured.Adverse cardiovascular events and complications were observed and compared between the two groups in the course of medication for 6 months.IBM SPSS200 statistical software package was used for statistical processing,the data rate was expressed by ?2 test,and the quantitative data± were expressed(?x±s)by mean standard error.Two groups were compared using t test,p<0.05 difference was statistically significant.ResultsThere was no significant difference between the groups in preoperative baseline data,blood glucose level and other indicators of PCI and there was no significant difference in platelet function index(CD62P,CD63andMPAR)before the operation of PCI.After PCI double anticoagulant therapy for two months,A,B two groups of platelet function index(CD62P,CD63andMPAR)were significantly decreased compared with that before treatment.In four months,the numerical index of platelet function continued to decline,and the difference was statistically significant between the two groups(P<0.05).And six months since the operation,the incidence of major adverse cardiovascular events of ticagrelor group was lower than that of the clopidogrel group,showing statistical significance in the difference between groups(p<0.05).ConclusionAcute Coronary Syndrome patients with type 2 diabetes mellitus patients after PCI,for ticagrelor combined with aspirin double anticoagulant therapy can effectively inhibit platelet function,reduce platelet aggregation rate.After 6 month,major adverse cardiovascular events rate is lowered the risk of bleeding is reduced.